ResearcherUniversity of Cape TownActive in the last 2 years

Philip J. Day

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0130-4797; OpenAlex author ID A5054081363. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 2)
Trials: 0
Grants: 0
Labs led: 1
Collaborators: 2

Papers, trials and grants by year

2026: 2 papers

Papers 2

Enhancement of gemcitabine toxicity and specificity through PI3K/Akt/Nrf2 pathway inhibition in pancreatic cancer. Last author DOI 10.3389/fphar.2026.1724989 ↗
Sensitising PDAC to Gemcitabine by Suppressing NF-κB Pathway and Enhancing Apoptosis. Last author DOI 10.3390/ph19020243 ↗

Closest collaborators

The 2 strongest of 2 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Yu-Shan Chen · 1 shared paper, 2026 · strength 0.50
- Paper Enhancement of gemcitabine toxicity and specificity through PI3K/Akt/Nrf2 pathway inhibition in pancreatic cancer. DOI 10.3389/fphar.2026.1724989 ↗
Enhui Jin · 1 shared paper, 2026 · strength 0.39
- Paper Sensitising PDAC to Gemcitabine by Suppressing NF-κB Pathway and Enhancing Apoptosis. DOI 10.3390/ph19020243 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.